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Summary: By immunization of mice with the anti-CA 125 monoclonal antibody OC125, we tried to induce
antibodies directed against the tumour-associated antigen CA 125, via activation of the idiotypic network.
Mice immunized by repeated administrations of F(ab')2-fragments of the OC125 antibody produced anti-
idiotypic antibodies, imitating the original target antigen of the OC125. After induction of these anti-idiotypic
antibodies (Ab2ß) a murine IgG-anti-CA 125 (Ab3) response was detected. The induction of idiotypic cascades
offers the possibility of immunization against tumour-associated antigens, without using the original antigen
and breaking antitumour tolerance.
Introduction ^ . . ,. . ^., , . u r ,type anti-idiotypic antibody has the shape of the
Niels Jerne postulated that the immune system con- original antigenic determinant and acts like an inter-
sists of a network of antibodies and lymphocytes nal image of the antigen. The other anti-idiotypic
which interact through complementary structures of antibodies are called Ab2a and Ab2y. The Ab2oc rec-
antibodies, anti-antibodies or anti-anti-antibodies (1). ognizes a non-antigen combining site idiotope some-
It is thus proposed that an antigen causes the pro- where on the hypervariable region; the Ab2y recog-
duction of antibodies (Abl), bearing different idi- nizes an idiotope in close proximity to the antigen
otopes characteristic for each antibody clone. These combining site but is not an internal image and may
idiotopes can act as antigens and stimulate the pro- be representative of recurrent intrastrain or intra-
duction of anti-idiotypic antibodies (Ab2), which con- species idiotopes. The Ab2y, like the Ab2ß, recognizes
trol the production of Abl, and which in turn are an idiotope within the antigen binding site, but fails
controlled by anti-anti-idiotypic antibodies (Ab3). to exhibit biological mimicry of the antigen. The Ab2ß
Within the set of anti-idiotypic antibodies directed f"™*™^ formation of anti-anti-idiotypic anti-
against the several idiotopes of Abl, some bind ex- bodies (Ab3>> ,which can a8ain bind to the Primary
actly to the antigen binding site. According to the ^ ^ ̂  /^ *"* ^ *" ****** ** °*
classification originally proposed by Jerne (2) and e '" > < ·
later modified by Bona & Köhler (3), these anti-idi- We previously demonstrated the appearance of anti-
otypic antibodies are designated as AbZß or so called idiotypic antibodies mimicking the tumour-associated
internal image anti-idiotype. The idiotope of an Ab2ß antigen CA 125, in ovarian cancer patients after re-
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peated treatment with F(ab')2-fragments of the anti-
CA 125 antibody OC125 (9). Induction of these anti-
idiotypic antibodies obviously leads to an improved
survival rate, even in advanced stages (10, 11), by
presumably breaking antitumour tolerance. A com-
mon explanation for the absence of antitumour im-
munity is that the immune system has been tolerized
by the tumour antigen (12). An effective method of
breaking this tolerance is to present the critical epitope
in a different molecular environment to the tolerized
host. According to the network hypothesis of Jerne
(1), one approach is the transformation of epitope
structures into idiotypic determinants expressed on
the surface of antibodies.
The aim of this study was to evaluate in an animal
model the induction of anti-idiotypic antibodies
(Ab2 ), which mimick the tumour-associated antigen
CA 125, i. e: to determine whether immunization with
F(ab')2-fragments of OC125 antibody subsequently
leads to the production of anti-anti-antibodies (Ab3)
directed against the target antigen CA 125.
Materials and Methods
Mate r i a l s
The F(ab')2-fragments of the monoclonal antibody OC125
M Ab, which bind to the tumour-associated-antigen CA 125,
were generously donated from International CIS, Filiale de
Compagnie ORIS Industrie S.A. (Gis-sur-Yvette, France).
The human ovarian adenocarcinoma ceil line OAW42 was
supplied by H. L hrke, Deutsches Krebsforschungszentrum
(Heidelberg, Germany) and cultured in RPMI medium (Bio-
chrom KG, Berlin. Germany), supplemented with fetal-calf
serum (Biochrom KG, Berlin, Germany), volume fraction 0.1,
2 mmol/1 L-glutamine (Boehringer-Mannheim, Mannheim,
Germany) and streptomycin/penicillin (Biochrom KG, Berlin,
Germany).
Ninety six-well flat bottom Dynatech microtitre plates were
obtained from Greiner GmbH & CoKG, N rtingen, Germany.
Globulin-free bovine serum albumin, peroxidase-labelled goat
anti-mouse-IgG (Fc-specific) and peroxidase-labelled goat anti-
mouse-IgM were purchased from Sigma Chemie GmbH (Dei-
senhofen, Germany) and used without further purification. The
peroxidase substrate, o-phenylenediamine, was obtained from
Zymed Laboratories Inc., San Francisco, USA. All other chem-
icals and solvents were obtained from Merck (Darmstadt, Ger-
many) or Aldrich (Steinheim, Germany).
Buffers
Buffer A:
0.1 mol/1 sodium phosphate, pH 7.4; 0.15 mol/1 NaCl
Buffer B:
0.5 mol/1 sodium citrate-phosphate pH 5.5; 3 ml/1 H2O2
Buffer C (Washing buffer):
0.1 mol/1 sodium phosphate, pH 7.4; 0.15 mol/1 NaCl, 1 ml/1
Tween 20
Buffer D (Blocking buffer):
0.1 mol/1 sodium phosphate, pH 7.4; 0.15 mol/1 NaCl, 10 g/1
bovine serum albumin
Buffer E (Incubation buffer):
0.1 mol/i sodium phosphate, pH 7.4; 0.15 mol/1 NaCl, 5g/l
bovine serum albumin
Immunization protocol
For immunization, F(ab)rfragments of the monoclonal anti-
body OC125 MAb were coupled to maleimide-activated key-
hole-limpet-haemocyanin (Pierce Chemical Co., Rockford,
USA) according to the product information. Female BALB/c
mice, 9 to 10 week old, received intraperitoneally 100 ̂ g F(ab)2-
fragments in incomplete Freund'* Adjuvant (Behring, Marburg,
Germany) on day 1, 31 and 61. The animals received a final
boost with 50 μg unconjugated F(ab)2-fragments of the mono-
clonal antibody OC125 MAb in buffer A on day 75. Blood
samples were collected on day 0 (control), 8, 38, 68 and 79.
Measurement of CA 125
CA 125 concentration was determined by the CA 125 El A
(Abbott Diagnostik, Wiesbaden-Delkenheim, Germany) ac-
cording to the instructions of the manufacturer.
Purif icat ion of CA 125
Culture supernatants of OAW42 celts, containing the CA 125
antigen, were collected after one week of cell growth and stored
at - 25 °C until use.
Ammonium sulphate fractionaiion
Ammonium sulphate (208 g/1) was added to the culture super-
natant. The mixture was centrifuged (10000 g, 20 min) and the
precipitate discarded. To the supernatant fraction, 163 g/1 am-
monium sulphate was added followed by a second centrifiga-
tion. The precipitate was resuspended in buffer A and dialysed
overnight against twenty volumes of buffer A.
Gel filtration on Superose 6
0.5 ml of the CA 125-containing ammonium sulphate fraction
(35 — 60% saturation) was applied to a Superose 6 column (1.5
χ 30 cm, Pharmacia, Freiburg, Germany), equilibrated with
buffer A. Fractions containing CA 125 (8 — 11 ml elution vol-
ume) were pooled and concentrated by Centricon-30 (Amicon,
Beverly, USA). Aliquotsofl ml (5000 χ 103 units/I) were stored
at -25°C until use.
Immunomet r i c assays
Microtitre plates were coated with F(abx)2-fragments of the
OC125 or with CA 125 overnight at 4°C in 100 μΐ coating
buffer A per well. The coated wells were then washed once with
washing buffer C (300 μΐ/well) and blocked with 200 μΐ buffer
D per well for l h at room temperature. After three washes
with buffer C, the immobilized antibody or antigen was incu-
bated for 18 h at 4°C with 100 μΐ/well of the serum samples
diluted in incubation buffer E. The plates were then washed
three times with buffer C and bound murine immunoglobuliris
were delected by incubation with peroxidase-labelled goat anti-
mouse IgG or IgM (diluted 1 :2000 or 1 : 5000, with buffer E)
for 2 h at 37 °C (100 μΐ/well). Following three washes, 100 μΐ
of substrate solution (1 g/1 o-phenylendiamine in buffer B) was
added. After incubation for 30 min at room temperature in the
dark, reaction was stopped by addition of 100 μί 0.5 mol/1
H2SO4 and absorbance was measured at 495 and 650 nm.
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la) Determination ofanίl·OCJ25 antibodies
For determination of the concentration of anti-OC125 anti-
bodies, 96-well Dynatech microtitre plates were coated with
F(ab')2-fragments of OC125 at a concentration of 2mg/l. Sera
of the immunized mice and the control samples were incubated
in different concentrations (diluted 1/100, 1/200, 1/400 and
1/800) and tested for bound mouse-IgG and mouse-IgM.
Ib) Inhibition of anti-OC125 antibody binding
To determine the portion of anti-OC125 antibodies bound to
the paratope of the OC125, an inhibition assay was performed.
Microlitre plates were coated as described above with 200 ng/
well of F(ab')2-fragments of OC125, then incubated with 50 μΐ/
well of the serum obtained on day 68 (diluted 1/100), together
with 50 μΐ purified CA"125 in rising concentrations (0.003 —
30000 χ 103 units/1) overnight at 4°C. Bound anti-OC125
antibodies were detected as described and the percentage of
inhibition was calculated in relation to serum incubated with
50 μΐ buffer E.
2a) Determination of anti-CA 125 antibodies
For determination of the concentration of anti-CA 125 anti-
bodies, microtitre plates were coated with 100 μΐ/well of a
solution of purified CA 125 (500 χ ΙΟ3 units/1) at 4°C over-
night, followed by incubation with 100 μΐ/weil of serum from
the immunized mice, or with control samples (diluted 1/100,
1/200, 1/400,1/800) overnight at 4 °C. After washing, the plates
were tested for bound mouse-IgG.
2b) Inhibition of anti-CA 125 antibody binding
For further characterization of anti-CA 125 antibodies, an
inhibition assay was performed. Microtitre plates were coated
as described above with 50 units/well of purified CA 125, then
incubated with 50 μΐ/well of the serum samples obtained on day
68, together with 50 μΐ purified CA 125 (concentration range:
104-10S units/1) overnight at 4°C. Bound anti-CA 125 was
detected as described and the percentage of inhibition was




In the purification procedure, the specific activity was
raised from 4.5 to 252.2 units/mg protein. By am-
monium sulphate precipitation, large amounts of IgG
and albumin were separated from fetal calf serum.
Chromatography on Superose 6 resulted in additional
separation of IgG, albumin and low molecular weight
proteins. The preparation showed no cross-reactivity
in immunoblots after isoelectric focussing.
Success of immunization
Before immunization with F(ab'):rfragments of the
OC125, no anti-OC125 or anti-CA 125 antibodies
could be detected (control samples one day before
immunization).
After treatment with OC125 F(ab')2-fragments, in-
creasing concentrations of anti-OC125 antibodies
were detected in sera of all mice (fig. 1). Antibodies
of the IgM type appeared immediately after the first
immunization and reached a maximum after the sec-
ond immunization. For antibodies of the IgG type,
the increase was delayed, and a maximum occurred
after the third boost (fig. 2).
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Fig. 1. The serum concentrations of anti-idiotypic IgG (Ab2 )
during the immunization protocol of 5 mice. Anti-idi-
otypic antibodies were detected on F(ab)2-OC125-
coated microtitre plates by peroxidase-labelled anti-
mouse IgG (Fc-specific) antibodies and 0-phenylenedi-
amine as substrate. The titre producing an absorbance
of 0.050 at 495 nm is given (Α — Δ mouse 1, α —α
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Fig. 2. Mean serum concentrations of anti-idiotypic antibodies
in 5 mice. Anti-idiotypic IgG (e — o) and IgM (n —n)
antibodies were determined during the immunization
protocol on F(ab)2-OC125-coated microtitre plates by
peroxidase-labelled anti-mouse IgG (Fc-specific) anti-
bodies or peroxidase-labelled anti-mouse IgM antibod-
ies and ϋ-phenylenediamine as substrate. The titre pro-
ducing an absorbance of 0.050 at 495 nm is given. Serum
samples were diluted 1/100 for IgG and 1/800 for IgM
analysis.
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The binding of anti-OC125 antibodies was inhibited
by the nominal antigen CA 125 in a concentration
dependent manner. Figure 3 demonstrates that the
binding of anti-OC125 antibodies could be inhibited
nearly completely by the addition of 30000 χ ΙΟ3
units/1 of CA 125. This indicates that most of the Ab2
recognize idiotopes at or near the binding site of the
OC125.
We also found increasing concentrations of anti-CA
125 antibodies in sera of mice after immunization (fig.
4). Murine anti-CA 125 antibodies were detected even
after the first immunization, and they reached a max-
100-1
o-*
- 1 0 1 2 3
log CA 125 [kU/l]
Fig. 3. Inhibition of the binding activity of anti-idiotypic IgG
by increasing concentrations of CA 125 antigen (A — A
mouse 1, D —α mouse 2, ο —β mouse 3, ο —ο mouse 4,
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Fig. 4. The serum concentrations of anti-anti-idiotypic IgG
(Ab3) during the immunization protocol of 5 mice. Anti-
anti-idiotypic antibodies were detected on CA 125-
coated microtitre plates by peroxidase-labelled anti-
mouse IgG (Fc-specific) antibodies and o-phenylenedi-
amine as substrate. The titre producing an absorbance
of 0.050 at 495 nm is given A — A mouse 1, · — α
mouse 2, ο — ο mouse 3, ο—ο mouse 4, α—α mouse 5).
imum after the second immunization. After the third
and fourth boost, the anti-CA 125 titre was stable or
slightly decreased.
The binding of these antibodies to immobilized CA
125 was inhibited by soluble CA 125 in a concentra-
tion dependent manner and the inhibition was nearly
complete at 100000 χ ΙΟ3 units/1 of CA 125 (fig. 5).
100η
0 1 2 3 4 5
log CA 125 [kU/l]
Fig. 5. Inhibition of the binding activity of anti-anti-idiotypic
IgG (anti-CA 125) by increasing concentrations of CA
125 antigen (A — A mouse 1, α —ο mouse 2, 0 — 0
mouse 3, ο —Ο mouse 4, a —d mouse 5).
The peroxidase-labelled goat anti-mouse-IgO (Fc-spe-
cific) did not bind to the F(ab)2-fragments of the
monoclonal antibody OC125 MAb. Incubation of
peroxidase-labelled goat anti-mouse-IgG (Fc-speeific)
in OC125 MAb-F(ab')2-coated microtitre plates
yielded in an absorbance of about 0.030 at 495 nm
after substrate addition, when read against similarly
treated uncoated microtitre plates.
Discussion
In support of previous hypotheses (1, 5) about the
activation of the idiotypic network and immunomo-
dulation by application of monoclonal antibodies, this
study demonstrates the induction of a murine anti-
OC125 and anti-CA 125 response by immunization
with OC125 F(ab')2-fragments.
As previously described for an ovarian cancer patient
»(9), we demonstrate in this study that repeated im-
munization with this murine antibody induces the
formation of anti-OC125 antibodies in mice. The
binding of these antibodies to OC125 F(ab')2-frag-
ments was inhibited by the CA 125 antigen, suggesting
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that the responsible IgG are anti-idiotypic antibodies
binding either at or near the paratope of the OC125
(Ab2ß or ). After immunization with murine anti-
bodies, humans form anti-isotypic and anti-allotypic
antibodies to antigenie determinants common on
mouse immunoglobulins, as well as highly specific
anti-idiotypic antibodies (13 — 17). In mice, however,
antibodies against idiotypic and allotypic determi-
nants can be expected. However, the fact that binding
of anti-OC125 antibodies was completely inhibited by
CA 125 indicates that there were no detectable con-
centrations of anti-allotypic antibodies. Also, anti-
idiotypic antibodies,- binding to idiotypes which are
not inhibited by the antigen, as demonstrated in pre-
vious studies (18, 19), obviously are not formed. This
is in concordance with our results in humans, where
binding of anti-idiotypic antibodies to OC125 was
inhibited completely by CA 125 (9). On the other
hand, the CA 125 molecule by virtue of its large size
(Mr about 200 000) may inhibit binding to many idi-
otopes by steric hindrance, so that it is difficult to
determine whether the Ab2 is Ab2ß or .
The inhibition curves of the five mouse sera showed
certain differences, which might be due to a set of
anti-idiotypic antibodies with different affinities.
According to the network hypothesis, anti-idiotypic
antibodies of the Ab2ß type imitate the original an-
tigen of the Abl and can serve as an internal image
of the nominal antigen. This internal image possibly
activates the idiotypic network by producing anti-
anti-idiotypic antibodies (Ab3), which bind to the
binding sites of both Ab2ß and the original antigen.
In the animal model, murine antibodies against the
tumour-associated antigen CA 125 were also detected.
The binding of these antibodies to immobilized CA
125 could be inhibited by purified soluble CA125,
which suggests that these antibodies bind specifically
to the CA 125 antigen. Appearance of these anti-CA
125 antibodies (Ab3) can be interpreted as the for-
mation of anti-idiotypic antibodies to the Ab2ß type
anti-idiotype which imitates the shape of the epitope
on the original antigen CA 125. Detection of Ab3
after immunization with Abl gives strong evidence
for the existence of an immunological network. An-
tibodies to CA 125 could not be induced by the CA
125 antigen itself, because the mice did not receive
any CA 125 and do not express the antigen. According
to the network theory, anti-CA 125 antibodies could
be provoked by internal image Ab2 against the anti-
CA 125 antibody. The variable regions of these Ab2,
expressing an mirror image of the CA 125 antigen,
are recognized by the immune system of the host and
can induce the formation of possibly regulatory Ab3>
which bind to the binding site of the Ab2 and to the
original antigen.
The inhibition curves and the inhibitory concentra-
tions of CA 125 were different in the examined sera,
indicating that, as for the Ab2, a set of anti-CA 125
antibodies with different affinities was formed.
In contrast, all attempts to demonstrate the existence
of circulating Ab3 in serum samples containing Ab2
were without success in tumour patients treated with
various monoclonal antibodies (8). Detection of Ab3
against a human antigen is of advantage in a model
of a different species. For example, mice, unlike hu-
mans, do not express the CA 125 antigen, so that
circulating anti-CA 125 antibodies cannot be bound
by CA 125-bearing tissues or circulating CA 125.
Presumably, not all Ab2 and Ab3 were detected by
the present tests. In an immunometric assay, anti-
idiotypic and anti-anti-idiotypic antibodies can be
detected if the hypervarible regions are accessible and
are not bound to circulating immune complexes in
the sera of the treated mice. Only if the immune
complexes of antigen, Abl, Ab2 and Ab3 dissociate
in the assay can they then be measured. In incubated
mixtures of Ab2, Ab3, OC125 and CA 125, individual
equilibria are established between the components,
and in cases where the affinity of the Ab3 to immo-
bilized CA 125 is greater than to Ab2, the antigen
can displace the Ab2 from the binding to Ab3, so
that the Ab3 becomes detectable in an assay.
Concerning the Ab2 detection in sera of immunized
mice, only anti-idiotypic antibodies with higher affin-
ity to the OC125 than to the Ab3 are detectable.
Anti-idiotypic antibodies were found in tumour pa-
tients after treatment with monoclonal antibodies of
different specificities (8, 9, 18, 20, 21). The induction
of anti-idiotype Ab2 is correlated with a delayed clin-
ical response in these patients (6, 8, 11, 22).
Our first results in patients with advanced ovarian
carcinomas indicate that, in spite of the same surgical
and chemotherapeutic treatment, the survival rate is
improved after vaccination with antibody-fragments
of the OC125 during repeated immunoscintigraphy
(10, 11). In these patients showing clinical benefit, the
appearance of anti-idiotypic antibodies was demon-
strated (9); furthermore, we found an induction of a
tumour-specific cellular immunity against autologous
tumour tissue, parallel to the production of anti-
idiotypic antibodies (23).
The present investigation demonstrates the activation
of the idiotypic network from Abl to Ab2 and at
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 7
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least the production of Ab3. The interpretation of the
immune system as an idiotypic network provides a
basis for inducing an alteration in the immuriological
response of a tumour patient, which specifically
breaks the existing antitumour tolerance, resulting in
a beneficial clinical response. Furthermore, this sys-
tem offers the possibility of immunization against
tumour-associated antigens without using the original
antigen.
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